SEC Form 4 · accession 0001209191-18-029521
Flexion Therapeutics Inc · FLXN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Neil Bodick
Officer — Chief Scientific Officer
Period of report
May 11, 2018
Accepted (ET)
May 11, 2018 · 4:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001419600
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 11, 2018 | M | 37,702 | $0.1626 | A | 112,307 | D | |
| Common Stock | holding | — | — | — | 1,000 | I | By spouse | |
| Common StockF1 | holding | — | — | — | 388,683 | I | By Versant Development Fund III, LLC |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F2 | $0.1626 | May 11, 2018 | M | 37,702 | D | — | Sep 23, 2019 | Common Stock | 37,702 | 0 | D |
Explanation of responses
- F1The shares are held by Versant Development Fund III, LLC. The Reporting Person is a manager and minority member of Versant Development Fund III, LLC. The Reporting Person disclaims any beneficial ownership of the shares held by Versant Development Fund III, LLC except to the extent of his pecuniary interest in these shares.
- F2The stock option is fully vested and exercisable.